Navigation Links
Actemra (tocilizumab) Third Phase III Study Results Show,Significant Improvement in Symptoms of Patients with Rheumatoid,Arthritis

ptoms and measures the number of tender and swollen joints, pain, patient's and physician's global assessments and certain laboratory markers. An ACR70 response is considered exceptional and represents a significant improvement in a patient's condition. (2) The Disease Activity Score (DAS)28 is a combined index that measures disease activity in patients with RA. It combines information from 28 tender and swollen joints (range 0-28), erythrocyte sedimentation rate, and a general health assessment on a visual analog scale. The level of disease activity is interpreted as low (DAS28 less than or equal to 3.2), moderate (3.2 < DAS28 less than or equal to 5.1) or high (DAS28 >5.1). DAS28 <2.6 corresponds to being in remission according to the criteria of the American Rheumatism Association (ARA). (3) The EULAR response criteria is based on the individual amount of change in DAS and the DAS value (low, moderate, high disease activity) reached to classify patients as good, moderate and non-responders.

CONTACT: Ginny Valenze of Roche, Office, +1-973-562-2373, Cell,+1-973-943-9219, ; or Becky Lauer of ManningSelvage & Lee, Office, +1-212-468-4125, Cell, +1-917-592-9260,, for Roche virginia.valenze@roche.com becky.lauer@mslpr.com

Web site: http://www.rocheusa.com/http://www.roche.us/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
2. Neurologix to Present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference
3. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
4. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
5. One-Third of Patients Discontinue Common Breast Cancer Therapy
6. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:3/27/2015)... NEW YORK , March 27, 2015 ... in Santa Ana, California is a ... market for which is estimated at $22 billion in the ... includes the use of FDA-approved Naltrexone in a specially compounded ... (excluding Australia and New ...
(Date:3/27/2015)... -- Levi & Korsinsky announces it has commenced an ... concerning possible violations of federal securities laws. The investigation ... with its study of the drug OHR-102. To obtain ... Joseph E. Levi, Esq. either via email ... 363-7500, toll-free: (877) 363-5972. Levi & Korsinsky ...
(Date:3/27/2015)... - Russell Williams , President of ... 2015-2016 Quebec Budget, noting the fiscal discipline and the ... However, the association is concerned about the decline of ... intent to strive for a balanced budget this year, ... Quebec,s economic development is encouraging," said Mr. ...
Breaking Medicine Technology:Small Cap IR Correction -- BioCorRx Inc. Positions Itself Through Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S. 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3
... Therapeutics (Nasdaq: NKTR ) will announce its financial ... Wednesday, November 2, 2011, after the close of U.S.-based financial ... a conference call to review the results beginning at 5:00 ... The press release and a live audio-only Webcast of ...
... Oct. 26, 2011 ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ... with the U.S. Food and Drug Administration (FDA) to ... ANX-514 (docetaxel for injectable emulsion), a detergent-free reformulation of ... study (Study 514-02) with a primary objective of comparing ...
Cached Medicine Technology:Nektar to Announce Financial Results for the Third Quarter of 2011 on Wednesday, November 2, 2011, After Close of U.S.-Based Financial Markets 2ADVENTRX and FDA Reach Agreement on Pivotal Study for ANX-514 2ADVENTRX and FDA Reach Agreement on Pivotal Study for ANX-514 3ADVENTRX and FDA Reach Agreement on Pivotal Study for ANX-514 4
(Date:3/29/2015)... 2015 Youth Villages will participate in ... to assess the feasibility of implementing a Pay for ... problems and their families. , Third Sector Capital Partners ... will be provided technical assistance throughout 2015 toward a ... other national awardees chosen by Third Sector. The organization’s ...
(Date:3/29/2015)... Chicago, IL (PRWEB) March 29, 2015 ... W. Brickner, “and as we learn more about the ... , In March Homeostasis: Publius’ Go Endo-Cannabinoid Update ... homeostatic health, or endo-healing, is celebrated. Publius, of The ... four 2015 National Institutes of Health (PubMed) cannabinoid system ...
(Date:3/28/2015)... March 28, 2015 Could genetic code ... new study by researchers at the Harvard ... with the support of the Coffee and Caffeine Genetics ... Psychiatry this past fall, the study—one of several recent ... genomic data from more than 120,000 regular coffee drinkers ...
(Date:3/28/2015)... 28, 2015 With more than ... fields of osteoporosis, osteoarthritis and musculoskeletal diseases gathered ... may be the first time in the 17-year ... that the hot-button topic is an emerging non-pharmaceutical ... well-accepted scientific principles of Wolff’s law, osteogenic loading ...
(Date:3/28/2015)... New York, NY (PRWEB) March 28, 2015 ... clinic that offers urgent care in Manhattan, recently commemorated ... urgent care facility in Manhattan. In addition to 24-hour ... to ER facilities. , At this time, Emergency ... treatments for abdominal pain, asthma, chest pain, eye injuries, ...
Breaking Medicine News(10 mins):Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 2Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 3Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 4Health News:March Homeostasis: Publius’ Go Endo-Cannabinoid Update ~ New on the Bryan William Brickner Blog 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2
... ... provides a central source for gaining insight, sharing opinions and finding resources on hospital ... ... launched an online community for hospitals: www.theQsphere.com . TheQsphere.com provides a central source ...
... Ky., June 15 VirtualHealth Technologies, Inc. (OTC Bulletin ... agreement to partner with Silk Information Systems, Inc. (SILK) ... and Billing solutions with no cost of entry to ... subsidiary Medical Office Software (MOS). , ...
... St. Louis, MO, June 15, 2009 Calcium and dairy ... of chronic disease. Because peak bone mass is not achieved ... for young adults to consume adequate amounts of calcium, protein ... and prevent osteoporosis later in life. In a study in ...
... Used to Develop DNA-Guided Decision Support for Statin Prescription ... biomedical company advancing DNA-guided medicine and personalized healthcare, announced ... Atherosclerosis, a meeting held triennially by the International Atherosclerosis ... present " Physiogenomic Contours of Statin Safety ...
... Amira Pharmaceuticals, Inc. announced today that it will present ... June 30, 2009 at the Federation of American Societies ... Arizona. , , The LPA1 receptor is part ... is associated with cell to cell communication. In recent ...
... Despite the severe economic downturn, assisted living remains enormously ... in a new national survey. , , The 2009 ... of the industry conducted by the leading senior living associations, ... a slight decrease from the 2006 survey when the economy ...
Cached Medicine News:Health News:New Online Community Answers Hospital Questions about ARRA QHR Announces Launch of theQsphere.com 2Health News:VirtualHealth and Silk Partner to Provide Physicians with Revenue Recovery Solutions 2Health News:VirtualHealth and Silk Partner to Provide Physicians with Revenue Recovery Solutions 3Health News:VirtualHealth and Silk Partner to Provide Physicians with Revenue Recovery Solutions 4Health News:VirtualHealth and Silk Partner to Provide Physicians with Revenue Recovery Solutions 5Health News:Young adults not drinking enough milk 2Health News:Genomas Presents Drug-Specific Genetic Determinants of Statin Safety and Efficacy at the XV International Symposium on Atherosclerosis 2Health News:Amira Pharmaceuticals to Present Preclinical Data from LPA1 Receptor Antagonist Program at FASEB Summer Research Conference 2Health News:Safety and Quality Contribute to Popularity of Assisted Living 2
... strong heritage in patient monitoring, IntelliVue has ... measurements menu; built-in clinical support tools such ... and arrhythmia analysis; and many other powerful ... and operates on a networked platform that ...
... is designed to match the pace and ... environments. Built on Philips strong heritage in ... independent displays has highly flexible screen configuration; ... support tools such as Event Surveillance, EASI ...
... Nightingale Monitoring System™ expands hospital-grade monitoring capabilities ... subacute care and disease state management. ... to encompass a full range of clinical ... inside the hospital, to periodic monitoring of ...
... Narkotron II is a comprehensive vital sign monitor. , ... quality, affordable products for efficiency in patient care., ... 2 - Temp - Multi-gas Sensor (HAL, ... )., ,Optional Functions: ,5-Lead ECG - FiO 2 ...
Medicine Products: